Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis

Apoptosis

Volumn 10, Issue 5, 2005, Pages 1131-1142

  Chen, J ^a   Ramos, J ^a   Sirisawad, M ^a   Miller, R ^a   Naumovski, L ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

Apoptosis; Caspase; Motexafin gadolinium; Q VD OPh; z VAD fmk

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GADOLINIUM TEXAPHYRIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION;

AMINO ACID CHLOROMETHYL KETONES; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; METALLOPORPHYRINS; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; QUINOLINES;

ANIMALIA;

EID: 24644441687     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-005-0887-2     Document Type: Article

References (27)

1. Magda D, Gerasimchuk N, Lecane P, et al. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb) 2002; 2730-2731.
2. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994; 29: 330-338.
3. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996; 93: 6610-6615.
4. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001; 51: 1025-1036.
5. Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001; 7: 3215-3221.
6. Xu S, Zakian K, Thaler H, et al. Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 2001; 49: 1381-1390.
7. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001; 19: 2074-2083.
8. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002; 20: 3445-3453.
9. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999; 5: 739-745.
10. Viala J, Vanel D, Meingan P, et al. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology 1999; 212: 755-759.
11. Evens AM. Motexafin gadolinium: A redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 2004; 16: 576-580.
12. Khuntia D, Mehta M. Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 2004; 4: 981-989.
13. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-2614.
14. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003; 8: 345-352.
15. Eray M, Tuomikoski T, Wu H, et al. Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype. Int Immunol 1994; 6: 1817-1827.
16. Epstein AL, Levy R, Kim H, et al. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 1978; 42: 2379-2391.
17. Borutaite V, Brown GC. Caspases are reversibly inactivated by hydrogen peroxide. FEBS Lett 2001; 500: 114-118.
18. Lui HM, Chen J, Wang L, Naumovski L. ARMER, apoptotic regulator in the membrane of the endoplasmic reticulum, a novel inhibitor of apoptosis. Mol Cancer Res 2003; 1: 508-518.
19. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
20. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897-907.
21. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-292.
22. Sun XM, MacFarlane M, Zhuang J, et al. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-5060.
23. Van Noorden CJ. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem 2001; 103: 241-251.
24. Garcia-Calvo M, Peterson EP, Leiting B, et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 32608-32613.
25. de Bruin EC, Meersma D, de Wilde J, et al. A serine protease is involved in the initiation of DNA damage-induced apoptosis. Cell Death Differ 2003; 10: 1204-1212.
26. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-1173.
27. Lorenzo HK, Susin SA. Mitochondrial effectors in caspase-independent cell death. FEBS Lett 2004; 557: 14-20.